ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
2,1,Hyperlipidaemia,Hyperlipidaemias NEC,Lipid metabolism disorders,Metab,N
3,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
4,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
5,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
6,1,Hyperlipidaemia,Hyperlipidaemias NEC,Lipid metabolism disorders,Metab,N
7,1,Hypertriglyceridaemia,Elevated triglycerides,Lipid metabolism disorders,Metab,N
8,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
8,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
8,3,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
9,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
9,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
9,3,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
10,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
11,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
12,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
13,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
13,2,Coagulation test abnormal,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
13,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
13,4,Haematemesis,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
13,5,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
13,6,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
13,7,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
14,1,Cardiac failure,Heart failures NEC,Heart failures,Card,Y
14,2,Lung opacity,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
15,1,Cutaneous T-cell lymphoma,Mycoses fungoides,Lymphomas non-Hodgkin's T-cell,Neopl,N
15,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
15,3,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
16,1,Hypertriglyceridaemia,Elevated triglycerides,Lipid metabolism disorders,Metab,N
16,2,Myalgia,Muscle pains,Muscle disorders,Musc,N
